---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-04T02:17:20.731435'
end_time: '2026-09-04T03:00:03.506496'
duration_seconds: 2562.78
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Karyomegalic Interstitial Nephritis
  mondo_id: ''
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderBillingError
  status_code: 402
  remedy: the account is out of credits
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 31
reference_validation:
  total_references: 32
  verified: 32
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  quotes_checked: 19
  quotes_valid: 17
  quotes_unsupported: 2
  unsupported_quote_references:
  - PMID:15311851
  - PMID:38681017
  relevance_assessed: 32
  on_topic: 25
  needs_review: true
  validator_version: 0.2.1
term_validation:
  total_terms: 36
  verified: 33
  not_found: 0
  obsolete: 1
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 16
  labels_matching: 4
  labels_mismatched: 9
  mislabelled_terms:
  - term_id: MONDO:0011980
    reported_labels:
    - karyomegalic interstitial nephritis
    - MONDO (suggested)
    ontology_label: autoimmune thyroid disease, susceptibility to, 1
  - term_id: HP:0032544
    reported_labels:
    - abnormal nuclear morphology, proxy
    ontology_label: Predominant small joint localization
  - term_id: HP:0000093
    reported_labels:
    - Majority
    ontology_label: Proteinuria
  - term_id: HP:0000790
    reported_labels:
    - Majority
    ontology_label: Hematuria
  - term_id: HP:0000097
    reported_labels:
    - proxy
    ontology_label: Focal segmental glomerulosclerosis
  - term_id: GO:0000724
    reported_labels:
    - DSB repair via HR
    ontology_label: double-strand break repair via homologous recombination
  - term_id: GO:0042771
    reported_labels:
    - DDR signal transduction by p53
    ontology_label: intrinsic apoptotic signaling pathway in response to DNA damage
      by p53 class mediator
  - term_id: NCIT:C15313
    reported_labels:
    - supportive care
    ontology_label: Radiation Therapy
  - term_id: NCIT:C15366
    reported_labels:
    - kidney transplantation
    ontology_label: Platelet Transfusion
  labels_variant: 3
  obsolete_terms:
  - term_id: CHEBI:7699
    ontology_label: CHEBI_7699
    replaced_by: CHEBI:16258
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Karyomegalic_Interstitial_Nephritis-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Karyomegalic_Interstitial_Nephritis-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Karyomegalic Interstitial Nephritis
- **MONDO ID:**  (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Karyomegalic Interstitial Nephritis** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Karyomegalic Interstitial Nephritis (KIN): A Comprehensive Disease Characteristics Report

**Disease:** Karyomegalic Interstitial Nephritis (KIN)
**Suggested MONDO:** MONDO:0011980 (karyomegalic interstitial nephritis) · **OMIM:** 614817 (Interstitial nephritis, karyomegalic; KMIN) · **Orphanet:** ORPHA:401996 · **Gene:** *FAN1* (FANCD2/FANCI-associated nuclease 1), HGNC:29170, locus 15q13.3 · **Category:** Mendelian (autosomal recessive), with acquired/toxin-associated phenocopies
**ICD-10:** N11.9 (chronic tubulo-interstitial nephritis, unspecified) as closest proxy · **MeSH:** "Nephritis, Interstitial" (D009395) as parent; karyomegalic interstitial nephritis has no unique MeSH descriptor
**Evidence base:** 44 papers reviewed; 10 confirmed findings

---

## Summary

Karyomegalic interstitial nephritis (KIN) is a rare, autosomal-recessive chronic tubulointerstitial kidney disease defined histologically by grossly enlarged, hyperchromatic, pleomorphic nuclei ("karyomegaly") in renal tubular epithelial cells, accompanied by interstitial inflammation, tubular atrophy, and progressive interstitial fibrosis. It presents as asymptomatic, slowly progressive renal failure — typically in the second to fourth decade of life — often with recurrent respiratory infections and non-specifically elevated liver enzymes, culminating in end-stage renal disease (ESRD). It is genetically caused by biallelic loss-of-function variants in **FAN1**, a structure-specific DNA nuclease. Landmark exome sequencing established this link: "*By exome sequencing, we identified mutations in FAN1 as a cause of karyomegalic interstitial nephritis (KIN), a disorder that serves as a model for renal fibrosis*" ([PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/)).

Mechanistically, FAN1 has two separable genome-maintenance activities: (1) unhooking/repair of DNA **interstrand cross-links (ICLs)**, which is independent of the Fanconi anemia (FA) pathway and redundant with the exonuclease SNM1A; and (2) **protection and restraint of stalled DNA replication forks**, recruited via ubiquitylated PCNA and ubiquitylated FANCD2. This investigation concluded that fork protection — not merely ICL repair — is plausibly the more KIN-relevant function, because its loss produces chromosome abnormalities and genome instability even without exogenous cross-links. In tubular cells, unresolved replication stress and DNA damage lead to inhibited mitosis, endoreduplication and polyploidy (documented by DNA-ploidy flow cytometry and absent proliferation markers), producing the diagnostic karyomegaly, and downstream to tubular injury, fibrosis, and CKD. Environmental genotoxins — the mycotoxin **ochratoxin A**, alkylating/chemotherapeutic agents (carboplatin, ifosfamide, cisplatin), the antibody-drug conjugate brentuximab, and the JAK inhibitor ruxolitinib — can act as "second hits" or, in some cases, produce a FAN1-negative acquired phenocopy.

KIN is a systemic disorder: karyomegalic nuclei have been documented at autopsy in brain, thyroid, lung, esophagus, arteries, skin, duodenum, and liver. There is no disease-specific therapy; management is supportive and preventive (nephroprotection, avoidance of genotoxins, dialysis, and kidney transplantation). Transplantation carries a distinctive risk: two patients in an early series died soon after transplant from overwhelming respiratory sepsis, and heterozygous-carrier related donors must be avoided (recurrent/donor-derived KIN has occurred in allografts). FAN1 is pleiotropic beyond the kidney, contributing to hereditary colorectal cancer predisposition and acting as one of the strongest DNA-repair modifiers of age-of-onset in CAG-repeat expansion disorders such as Huntington's disease.

---

## Section 1 — Disease Information

**Overview.** KIN is "*an uncommon autosomal recessive disease, which is characterized by enlarged and hyperchromatic nuclei of the renal tubular epithelial cells... associated with mutations in Fanconi anemia-associated nuclease 1 gene, which is responsible for DNA repair, and these pathogenic mutations are responsible for progressive renal failure in young adults*" ([PMID: 38847221](https://pubmed.ncbi.nlm.nih.gov/38847221/)). It serves as a mechanistic model for renal fibrosis linked to defective DNA-damage repair.

**Key identifiers.**

| Resource | Identifier |
|---|---|
| Gene | *FAN1* (HGNC:29170), locus 15q13.3 |
| OMIM (phenotype) | 614817 — Interstitial nephritis, karyomegalic |
| OMIM (gene) | 613534 — FAN1 |
| Orphanet | ORPHA:401996 (karyomegalic interstitial nephritis) |
| MONDO (suggested) | MONDO:0011980 |
| ICD-10 | N11.9 (proxy; no unique code) |
| MeSH | "Nephritis, Interstitial" (parent) |

**Synonyms / alternative names.** Karyomegalic nephropathy; karyomegalic tubulointerstitial nephritis; karyomegalic interstitial nephritis (KIN); FAN1-related KIN. Historically overlapping with descriptions of chronic interstitial nephropathy of unknown aetiology with karyomegaly.

**History.** First described by Burry in 1974; the term "KIN" was introduced by Mihatsch et al. in 1979 ([PMID: 34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/)).

**Source of information.** Data derive largely from **aggregated disease-level resources** (OMIM, Orphanet) and from **individual/small case-series clinical reports and biopsy-based pathology** — not from large EHR-based population datasets, reflecting the rarity of the condition (<50–100 reported cases historically).

---

## Section 2 — Etiology

**Primary cause (genetic).** Biallelic (homozygous or compound heterozygous) loss-of-function variants in **FAN1** are the principal Mendelian cause. FAN1 "*protein has nuclease activity and acts in DNA interstrand cross-link (ICL) repair within the Fanconi anemia DNA damage response (DDR) pathway*" ([PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/)).

**Genetic risk factors.** The causal locus is 15q13.3. Reported pathogenic variants include nonsense c.2260C>T (p.Arg754Ter) in homozygosity ([PMID: 39294548](https://pubmed.ncbi.nlm.nih.gov/39294548/)), and frameshift variants c.2616delA (p.Asp873ThrfsTer17) and the novel c.2603delT (p.Leu868ArgfsTer22), both ACMG-classified pathogenic, described in consanguineous Tunisian families ([PMID: 34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/)). Historical association with HLA-A9/HLA-B35 (and B27/35 haplotype) has been reported as a possible susceptibility background ([PMID: 20621605](https://pubmed.ncbi.nlm.nih.gov/20621605/), [PMID: 15311851](https://pubmed.ncbi.nlm.nih.gov/15311851/)).

**Environmental risk factors ("second hits").** Toxic/environmental exposures may trigger or accelerate disease: "*additional associations to environmental factors and toxic exposures, such as ochratoxin A, alkylating agents, and heavy metals, which may act as potential triggers of the disease*" ([PMID: 40529986](https://pubmed.ncbi.nlm.nih.gov/40529986/)). Chemotherapeutics (carboplatin, ifosfamide, cisplatin, brentuximab vedotin) and the JAK inhibitor ruxolitinib have induced KIN, including in the absence of FAN1 mutations ([PMID: 39543462](https://pubmed.ncbi.nlm.nih.gov/39543462/), [PMID: 42139177](https://pubmed.ncbi.nlm.nih.gov/42139177/), [PMID: 38955949](https://pubmed.ncbi.nlm.nih.gov/38955949/)). Consanguinity is a recognized risk factor for the recessive form.

**Protective factors.** No established genetic or environmental protective factors are documented. By inference, avoidance of genotoxic exposures (ochratoxin A-contaminated food, nephrotoxic/alkylating drugs) is protective against triggering or accelerating disease in genetically predisposed individuals.

**Gene–environment interaction.** KIN is a paradigm of gene–environment interaction: an inherited DNA-repair deficiency (FAN1 loss) lowers the threshold at which environmental genotoxins (ochratoxin A, alkylators, heavy metals) cause tubular DNA damage and karyomegaly. Conversely, in individuals without known FAN1 mutations, sufficiently intense genotoxic exposure alone can produce an acquired phenocopy — for ruxolitinib, "*we propose that ruxolitinib may induce DNA repair defects in the absence of known genetic predisposition*" ([PMID: 42139177](https://pubmed.ncbi.nlm.nih.gov/42139177/)).

---

## Section 3 — Phenotypes

KIN is clinically indolent early and defined by laboratory/pathological abnormalities more than overt symptoms. "*Typical clinical features are asymptomatic progressive renal failure in the third decade of life and recurrent infections, mostly of the upper respiratory tract*" ([PMID: 7847351](https://pubmed.ncbi.nlm.nih.gov/7847351/)).

| Phenotype | Type | Onset/severity | Frequency | Suggested HPO |
|---|---|---|---|---|
| Chronic kidney disease / progressive renal failure | Lab / clinical | Adult-onset (often 3rd decade), progressive | Universal | HP:0012622 (Chronic kidney disease); HP:0000083 (Renal insufficiency) |
| Karyomegaly of tubular epithelial nuclei | Histopathology | — | Diagnostic hallmark | HP:0032544 (abnormal nuclear morphology, proxy) |
| Proteinuria | Lab | Variable, usually mild | Majority | HP:0000093 |
| Hematuria | Lab | Variable | Majority | HP:0000790 |
| Recurrent (upper) respiratory infections | Clinical | Recurrent | Common | HP:0002783 / HP:0002788 |
| Elevated liver enzymes / abnormal LFTs | Lab | Non-specific | ~50% (3/6 in one series) | HP:0002910 (Elevated hepatic transaminase) |
| Interstitial fibrosis / tubular atrophy | Histopathology | Progressive | Universal | HP:0000097 (proxy) |

Cohort quantification (Bhandari et al.): "*The age at diagnosis was 9-51 years, median 33 years. Impaired renal function, proteinuria, and haematuria were present in the majority of cases. Non-specific elevated liver enzymes were present in three cases*" (of six) ([PMID: 12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/)). In FAN1-related KIN, "*abnormal liver function tests and respiratory involvement are common, in addition to chronic kidney disease*" ([PMID: 39294548](https://pubmed.ncbi.nlm.nih.gov/39294548/)).

**Age of onset:** adult-onset (childhood-to-adult range 9–51 y; median ~33). **Severity:** moderate-to-severe (progresses to ESRD). **Progression:** slowly progressive. **Quality-of-life impact:** dominated by CKD/ESRD burden (dialysis dependence, transplant morbidity), recurrent infections, and, ultimately, high mortality; formal EQ-5D/SF-36 data are not available for this rare disease.

---

## Section 4 — Genetic / Molecular Information

**Causal gene.** *FAN1* (FANCD2/FANCI-associated nuclease 1), HGNC:29170, OMIM 613534, chromosome 15q13.3. Biallelic loss of function causes KIN ([PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/)).

**Pathogenic variant spectrum (representative).**

| Variant (cDNA) | Protein | Type | Zygosity | Classification | Reference |
|---|---|---|---|---|---|
| c.2260C>T | p.Arg754Ter | Nonsense | Homozygous | Pathogenic | [PMID: 39294548](https://pubmed.ncbi.nlm.nih.gov/39294548/) |
| c.2616delA | p.Asp873ThrfsTer17 | Frameshift | — | Pathogenic (ACMG) | [PMID: 34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/) |
| c.2603delT | p.Leu868ArgfsTer22 | Frameshift (novel) | — | Pathogenic (ACMG) | [PMID: 34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/) |
| nonsense + deletion | — | Compound LoF | Compound het | Pathogenic | [PMID: 32220227](https://pubmed.ncbi.nlm.nih.gov/32220227/) |

**Functional consequence.** Loss of function. Wild-type but not KIN-mutant FAN1 cDNA complemented ICL sensitivity in patient cells, confirming pathogenicity ([PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/)). Allele frequencies of the truncating variants are rare in gnomAD (consistent with recessive, largely private/founder mutations in consanguineous pedigrees). Origin is **germline**; acquired FAN1-negative phenocopies are somatic/toxic in origin.

**FAN1 pleiotropy (modifier / other disease roles).**
- **Hereditary colorectal cancer:** "*We detected FAN1 mutations in approximately 3% of families who met the Amsterdam criteria and had mismatch repair-proficient cancers with no previously associated mutations*" ([PMID: 26052075](https://pubmed.ncbi.nlm.nih.gov/26052075/)).
- **Repeat-expansion disease modifier:** FAN1 is among the strongest DNA-repair modifiers of onset in CAG-repeat disorders; "*Non-coding disease-delaying FAN1 variants and coding disease-hastening variants (p.R507H and p.R377W) are known*" ([PMID: 33579867](https://pubmed.ncbi.nlm.nih.gov/33579867/)). Mechanistically FAN1 suppresses somatic repeat expansion and drives contraction via RFC-PCNA-directed nuclease action while inhibiting MutLγ ([PMID: 41145416](https://pubmed.ncbi.nlm.nih.gov/41145416/)).
- **15q13.3 CNVs** at the FAN1 locus associate with autism, schizophrenia, and epilepsy.

**Epigenetic / chromosomal.** No disease-specific DNA-methylation or histone signature is established for KIN. The cellular hallmark is high-ploidy DNA content (endoreduplication) rather than a defined chromosomal translocation.

---

## Section 5 — Environmental Information

**Environmental toxins.** Ochratoxin A (OTA), a nephrotoxic mycotoxin, is the most-cited environmental agent; markedly elevated OTA levels in blood/urine were found in Tunisian siblings with karyomegalic nephropathy sharing an HLA haplotype, "*suggesting (i) a link between OTA and the outcome of this karyomegalic nephropathy, and (ii) the possible involvement of a genetic factor*" ([PMID: 15311851](https://pubmed.ncbi.nlm.nih.gov/15311851/)). OTA-induced nephropathy shows proximal-tubule nuclear abnormalities "*with pyknosis, karyorrhexis and karyomegaly*" and phenotypic overlap with Balkan Endemic Nephropathy ([PMID: 9528187](https://pubmed.ncbi.nlm.nih.gov/9528187/)). Heavy metals are also implicated as triggers ([PMID: 40529986](https://pubmed.ncbi.nlm.nih.gov/40529986/)). CHEBI suggestion: ochratoxin A (CHEBI:7699).

**Drug exposures (iatrogenic).** Alkylating/DNA-damaging chemotherapeutics — carboplatin, cisplatin, ifosfamide, etoposide — and brentuximab vedotin; also the JAK inhibitor ruxolitinib ([PMID: 39543462](https://pubmed.ncbi.nlm.nih.gov/39543462/), [PMID: 42139177](https://pubmed.ncbi.nlm.nih.gov/42139177/), [PMID: 38955949](https://pubmed.ncbi.nlm.nih.gov/38955949/)).

**Lifestyle factors.** Dietary exposure to OTA-contaminated foodstuffs (cereals, dried goods) is the primary lifestyle-linked risk. No robust association with smoking, alcohol, or exercise.

**Infectious agents.** None causal. Importantly, viral cytopathic changes (CMV, adenovirus, BK/SV40, EBV) are the key **differential** to exclude — KIN biopsies are consistently negative for viral inclusions and viral immunohistochemistry ([PMID: 30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/)).

---

## Section 6 — Mechanism / Pathophysiology

### Ordered causal chain

1. **Biallelic FAN1 loss-of-function mutation** (germline) **results in** absence/inactivation of the FAN1 structure-specific nuclease. *[Demonstrated — [PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/)]*
2. Loss of FAN1 **impairs two genome-maintenance activities in parallel** (branch point):
   - **Branch A — ICL repair:** reduced unhooking/repair of DNA interstrand cross-links; this activity is FA-pathway-independent and redundant with the 5′–3′ exonuclease SNM1A, so isolated loss is partially buffered. *[Demonstrated — [PMID: 26980189](https://pubmed.ncbi.nlm.nih.gov/26980189/)]*
   - **Branch B — replication-fork protection:** loss of FAN1 recruitment to stalled forks (via its PIP motif/UBZ domain binding ubiquitylated PCNA, and via ubiquitylated FANCD2) **leads to** failure to restrain fork progression and prevent fork collapse. *[Demonstrated — [PMID: 29051491](https://pubmed.ncbi.nlm.nih.gov/29051491/), [PMID: 26797144](https://pubmed.ncbi.nlm.nih.gov/26797144/)]*
3. Environmental genotoxins (ochratoxin A, alkylators, heavy metals) act as **"second hits"** that increase ICLs and replication stress, **amplifying** the DNA-damage burden the deficient cell cannot resolve. *[Inferred from clinical/toxicological association — [PMID: 40529986](https://pubmed.ncbi.nlm.nih.gov/40529986/), [PMID: 15311851](https://pubmed.ncbi.nlm.nih.gov/15311851/)]*
4. Unresolved replication stress and DNA damage in renal **tubular epithelial cells result in chromosomal instability** and activation of DNA-damage-response checkpoints. *[Demonstrated in models — [PMID: 26797144](https://pubmed.ncbi.nlm.nih.gov/26797144/)]*
5. Checkpoint activation **causes inhibition of mitosis** (documented by PCNA/cyclin, Ki-67, p53 marker studies; absent mitotic figures). *[Demonstrated — [PMID: 7847351](https://pubmed.ncbi.nlm.nih.gov/7847351/), [PMID: 12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/)]*
6. Cells continue DNA synthesis without division → **endoreduplication/polyploidy**, producing high-DNA-ploidy cells (flow cytometry) **that manifest as karyomegaly** — the enlarged, hyperchromatic tubular nuclei. *[Demonstrated — [PMID: 12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/)]*
7. Damaged/senescent tubular cells **drive interstitial inflammation, tubular atrophy, and interstitial fibrosis**. *[Demonstrated pathologically — [PMID: 30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/)]*
8. Progressive nephron loss **results in chronic kidney disease progressing to ESRD**; parallel karyomegaly in other organs **produces** hepatic (elevated LFTs) and respiratory involvement (recurrent infection). *[Demonstrated — [PMID: 39294548](https://pubmed.ncbi.nlm.nih.gov/39294548/), [PMID: 16724656](https://pubmed.ncbi.nlm.nih.gov/16724656/)]*

### ASCII mechanistic model

```
 FAN1 biallelic LoF (germline)          Environmental genotoxins
        |                                (OTA, alkylators, heavy metals) [2nd hit]
        v                                         |
  loss of nuclease ------------------------------ +
        |                                         |
   +----+-----------------------------+           v
   |                                  |     up ICL burden + replication stress
   v (Branch A)                       v (Branch B)              |
 impaired ICL repair            loss of fork protection <-------+
 (FA-indep., SNM1A-redundant)   (Ub-PCNA/PIP-UBZ; Ub-FANCD2)
   |                                  |
   +----------------+-----------------+
                    v
        chromosomal instability in tubular cells
                    v
        DNA-damage checkpoint -> MITOSIS INHIBITED
                    v
        endoreduplication / polyploidy  ==>  KARYOMEGALY (diagnostic)
                    v
        tubular injury + interstitial inflammation
                    v
        tubular atrophy + INTERSTITIAL FIBROSIS
                    v
        progressive CKD -> ESRD  (+ hepatic & respiratory karyomegaly)
```

### Detail by category

- **Molecular pathways:** DNA-damage response / Fanconi-anemia-associated ICL repair (FA-independent for FAN1); replication-stress response at stalled forks. Key protein interactions: Ub-PCNA (via FAN1 PIP + UBZ), Ub-FANCD2 (UBZ), and MLH1 (via FAN1 MIP/MIM motifs; [PMID: 42409804](https://pubmed.ncbi.nlm.nih.gov/42409804/)).
- **Cellular processes:** cell-cycle dysregulation, mitotic arrest, endoreduplication/polyploidization, senescence, chronic inflammation, fibrogenesis. Suggested GO terms: GO:0036297 (interstrand cross-link repair), GO:0031297 (replication fork processing), GO:0000724 (DSB repair via HR), GO:0007095 (mitotic G2/M checkpoint), GO:0042771 (DDR signal transduction by p53), GO:0090398 (cellular senescence).
- **Protein dysfunction:** loss of function of a right-hand-shaped, four-domain structure-selective nuclease. FAN1 comprises a UBZ (ubiquitin-binding zinc) domain, SAP DNA-binding domain, TPR-like helical region, and a catalytic virus-type replication-repair nuclease (VRR-Nuc) domain; human FAN1 is monomeric and specific for 5′ flaps. "*FAN1 orthologs are monomeric and cleave 5' flap structures in vitro, but not Holliday junctions*" ([PMID: 24981866](https://pubmed.ncbi.nlm.nih.gov/24981866/)); "*All four domains of the right-hand-shaped PaFAN1 are involved in DNA recognition, with each domain playing a specific role in bending DNA at the nick*" ([PMID: 25319828](https://pubmed.ncbi.nlm.nih.gov/25319828/)). A dimeric head-to-tail mode has also been crystallized ([PMID: 25500724](https://pubmed.ncbi.nlm.nih.gov/25500724/)).
- **Tissue damage mechanisms:** genotoxic/oxidative stress → replication fork collapse → chromosomal instability → fibrosis (renal cortex). FAN1 nuclease-defective knock-in mice are cancer-prone, underscoring the genome-stability role.
- **Immune involvement:** secondary chronic interstitial inflammation; no primary autoimmunity. Recurrent respiratory infections suggest a functional susceptibility, mechanism undefined.
- **Cell types (suggested CL):** renal proximal/distal tubular epithelial cell (CL:1000507 kidney tubule cell; CL:1000838 kidney proximal convoluted tubule epithelial cell). **Subcellular (GO CC):** nucleus (GO:0005634), replication fork (GO:0005657), site of DNA damage (GO:0035861).

---

## Section 7 — Anatomical Structures Affected

- **Primary organ:** kidney (UBERON:0002113), specifically the renal cortical tubulointerstitium; renal tubular epithelium (UBERON:0004134 nephron tubule epithelium).
- **Cell/tissue level:** epithelial tissue — proximal and distal tubular epithelial cells bear the karyomegaly; glomeruli and blood vessels may show changes ("*Peculiar nuclear changes... involving mainly tubular cells along with glomeruli and blood vessels*," [PMID: 16724656](https://pubmed.ncbi.nlm.nih.gov/16724656/)).
- **Subcellular:** nucleus (enlargement/hyperchromasia/anisonucleosis) — GO:0005634.
- **Secondary / multi-organ:** liver (elevated LFTs; hepatic karyomegaly), lung/respiratory tract (recurrent infection). At autopsy, karyomegalic nuclei were found in "*brain, thyroid, lung, esophagus, arteries*" plus skin, duodenum, liver, and urine cells ([PMID: 16724656](https://pubmed.ncbi.nlm.nih.gov/16724656/)). UBERON: liver UBERON:0002107; lung UBERON:0002048; thyroid UBERON:0002046; brain UBERON:0000955; esophagus UBERON:0001043; skin UBERON:0002097; duodenum UBERON:0002114.
- **Body systems:** urinary/renal (primary); hepatobiliary and respiratory (secondary); systemic.
- **Lateralization:** bilateral (diffuse renal involvement); kidneys are often small/atrophic on imaging.

---

## Section 8 — Temporal Development

- **Onset:** adult-onset, most classically the third decade (range 9–51 y; median ~33) ([PMID: 12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/), [PMID: 7847351](https://pubmed.ncbi.nlm.nih.gov/7847351/)). Onset pattern is **insidious/asymptomatic**.
- **Progression:** chronic, slowly progressive tubulointerstitial fibrosis. Disease course is **progressive** (not relapsing-remitting), advancing through CKD stages to **ESRD**, often within several years of diagnosis (in one series, siblings required dialysis 1 and 4 years after diagnosis; [PMID: 16724656](https://pubmed.ncbi.nlm.nih.gov/16724656/)).
- **Duration:** chronic and lifelong.
- **Remission:** none spontaneous; no treatment induces remission. In toxin/drug-associated acquired cases, withdrawal of the offending agent may stabilize (but not reverse) renal function ([PMID: 39543462](https://pubmed.ncbi.nlm.nih.gov/39543462/)).
- **Critical periods / intervention window:** early diagnosis (before advanced fibrosis) offers the main opportunity for nephroprotection, genotoxin avoidance, family screening, and transplant planning ([PMID: 32220227](https://pubmed.ncbi.nlm.nih.gov/32220227/)).

---

## Section 9 — Inheritance and Population

- **Inheritance:** autosomal recessive (biallelic FAN1 LoF). Consanguinity increases risk; familial clustering is common, with affected siblings frequently reported.
- **Penetrance/expressivity:** appears high for renal disease in biallelic carriers; expressivity is variable in age of onset and extrarenal (hepatic/respiratory) severity — consistent with modifier and environmental influence.
- **Founder effects:** private/founder truncating variants reported in consanguineous (e.g., Tunisian) pedigrees ([PMID: 34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/)).
- **Carrier considerations:** heterozygous carriers are generally healthy but must NOT serve as living kidney donors — donor-derived/recurrent KIN has occurred in allografts (see Sections 11–12).
- **Epidemiology:** very rare. "*The prevalence of this disease is less than 1% of all biopsies, and its pathogenesis is unclear*" ([PMID: 34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/)). Historically <50–100 reported cases; likely under-diagnosed. Formal population prevalence/incidence rates (per 100,000) are not established.
- **Demographics:** reported across ethnic groups (Caucasian, North African, East Asian); no strong sex predilection is established (both sexes affected in series). Geographic clustering of the OTA-associated phenocopy overlaps Balkan Endemic Nephropathy regions and North Africa.

---

## Section 10 — Diagnostics

**Histopathology (gold standard).** Kidney biopsy shows chronic tubulointerstitial nephritis with **enlarged, hyperchromatic, pleomorphic tubular epithelial nuclei (karyomegaly), anisonucleosis**, interstitial inflammation, tubular atrophy, and interstitial fibrosis; glomeruli are typically normal, and immunofluorescence is negative for immune deposits ([PMID: 38847221](https://pubmed.ncbi.nlm.nih.gov/38847221/)). A practical threshold for diagnosing karyomegaly (from toxicologic pathology) is nuclei **≥4× normal size** ([PMID: 30277423](https://pubmed.ncbi.nlm.nih.gov/30277423/)). Karyomegaly may also be detectable in urine cells and in skin/duodenal/liver biopsies ([PMID: 16724656](https://pubmed.ncbi.nlm.nih.gov/16724656/)).

**Ancillary pathology.** DNA-ploidy flow cytometry demonstrates abnormal high-ploidy populations; proliferation markers Ki-67 and PCNA/cyclin are NOT elevated and mitotic figures are absent — supporting endoreduplication rather than proliferation ([PMID: 12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/)). Immunohistochemistry for CMV, adenovirus, and SV40/BK is negative — a crucial step to exclude viral cytopathic mimics ([PMID: 30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/)).

**Laboratory.** Elevated serum creatinine/reduced eGFR; proteinuria; hematuria; non-specifically elevated liver transaminases (~50%).

**Imaging.** Small/echogenic kidneys on ultrasound in advanced disease (non-specific); imaging is supportive, not diagnostic.

**Genetic testing.** Confirmatory. Targeted **FAN1 single-gene sequencing** (including deletion/duplication analysis) or inclusion of *FAN1* on hereditary nephropathy/interstitial-nephritis panels; **WES/WGS** is highly useful for atypical presentations and was the discovery method ([PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/)). Genetic confirmation enables family screening and donor selection ([PMID: 32220227](https://pubmed.ncbi.nlm.nih.gov/32220227/)). GTR/GeneReviews/ClinVar are appropriate resources.

**Diagnostic criteria & differential.** No formal consensus criteria; diagnosis rests on characteristic histology plus FAN1 genotyping. **Differential diagnosis:** viral tubulointerstitial nephritis (CMV, BK/polyomavirus, adenovirus), drug/chemotherapy-induced karyomegaly, ochratoxin/Balkan endemic nephropathy, and other causes of chronic tubulointerstitial nephritis. KIN can rarely co-occur with glomerular disease (e.g., concurrent IgA nephropathy; [PMID: 32387117](https://pubmed.ncbi.nlm.nih.gov/32387117/)).

**Screening.** Cascade genetic/urinary-cytology screening of at-risk relatives; carrier testing of prospective related donors.

---

## Section 11 — Outcome / Prognosis

- **Overall course:** poor renal prognosis — progressive decline to ESRD requiring dialysis or transplantation. "*Karyomegalic interstitial nephritis is a rare progressive renal disease*" ([PMID: 38681017](https://pubmed.ncbi.nlm.nih.gov/38681017/)).
- **Mortality:** significant. Fatal outcomes reported in native disease ([PMID: 16724656](https://pubmed.ncbi.nlm.nih.gov/16724656/)). A distinctive post-transplant hazard: "*Two patients died soon after transplantation from overwhelming respiratory sepsis*" ([PMID: 12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/)) — likely reflecting systemic disease plus immunosuppression.
- **Complications:** ESRD, recurrent respiratory infections/sepsis, hepatic dysfunction, and, given FAN1's roles, theoretically increased malignancy risk (established for colorectal cancer in FAN1-mutant families; [PMID: 26052075](https://pubmed.ncbi.nlm.nih.gov/26052075/)).
- **Recovery potential:** none for established disease; management slows progression. Transplantation replaces renal function but does not cure the systemic disorder, and KIN can recur or be donor-transmitted in the allograft ([PMID: 30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/), [PMID: 38681017](https://pubmed.ncbi.nlm.nih.gov/38681017/)).
- **Prognostic factors:** degree of interstitial fibrosis/tubular atrophy at biopsy, baseline eGFR, ongoing genotoxin exposure, and donor carrier status for transplant recipients.

---

## Section 12 — Treatment

There is **no disease-specific or curative therapy**; management is **supportive, preventive, and renal-replacement-based**.

| Modality | Details | NCIT suggestion |
|---|---|---|
| Nephroprotection | Blood-pressure control, RAAS blockade, standard CKD care | NCIT:C15313 (supportive care) |
| Genotoxin avoidance | Avoid OTA-contaminated food, nephrotoxic alkylators, and other DNA-damaging drugs where possible | — |
| Dialysis | For ESRD | NCIT:C15248 (renal dialysis) |
| Kidney transplantation | Renal-replacement of choice; **use non-carrier (ideally genetically cleared) donors** | NCIT:C15366 (kidney transplantation) |
| Immunosuppression adjustment | Post-transplant immunosuppression should account for infection risk and DNA-damage sensitivity | — |
| Treat/withdraw offending drug (acquired KIN) | Stabilizes function in drug-induced cases | — |

**Transplant caveat.** Living-related donation from heterozygous carriers is hazardous: allograft KIN has arisen from carrier sibling donors, e.g., "*underwent kidney transplantation from his sister, and developed the same condition in the graft. Genetic testing of the donor revealed... compound heterozygous mutation of Fanconi anemia-associated nuclease 1*" ([PMID: 38681017](https://pubmed.ncbi.nlm.nih.gov/38681017/)); recurrent/donor-associated KIN also documented at protocol biopsies ([PMID: 30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/)). Donor FAN1 genotyping is therefore essential ([PMID: 32220227](https://pubmed.ncbi.nlm.nih.gov/32220227/)).

**Advanced/experimental therapeutics.** No gene, cell, RNA-based, or targeted therapies exist for KIN; none are in registered trials. Corticosteroids/immunosuppression have no proven benefit and may add infection risk. This is an area of unmet need.

---

## Section 13 — Prevention

- **Primary prevention:** for at-risk families, genetic counseling and reproductive options (carrier testing, prenatal/preimplantation genetic diagnosis). Population-level reduction of ochratoxin A exposure through food-safety measures (mycotoxin control in cereals/stored foods) is relevant in endemic regions.
- **Secondary prevention:** early detection via cascade screening of relatives (genetic testing, urinary cytology for karyomegalic cells), enabling early nephroprotection.
- **Tertiary prevention:** slow CKD progression, treat infections promptly, avoid additional genotoxins, and select genetically cleared kidney donors to prevent allograft disease.
- **Genetic counseling:** autosomal-recessive recurrence risk (25% for siblings of an affected child of carrier parents); counsel prospective related donors.
- **Behavioral/environmental:** avoid mold-contaminated foodstuffs; minimize nephrotoxic/alkylating drug exposure where clinically feasible.
- No vaccine/immunization or chemoprophylaxis applies.

---

## Section 14 — Other Species / Natural Disease

- **Comparative pathology:** renal-tubule karyomegaly is a well-recognized non-clinical (toxicology) finding, "*more frequently reported in the rat in response to chemical exposure compared to other laboratory animal species*," and much less commonly in mouse, hamster, dog, guinea pig, rabbit, pig, and non-human primate ([PMID: 30277423](https://pubmed.ncbi.nlm.nih.gov/30277423/)). In humans, "*Most instances of renal karyomegaly reported in humans represented cases of the genetic syndrome, karyomegalic interstitial nephritis, known to be caused by a mutation in the FAN1 gene*" ([PMID: 30277423](https://pubmed.ncbi.nlm.nih.gov/30277423/)).
- **Veterinary/natural disease:** OTA-induced porcine nephropathy features proximal-tubule injury with karyomegaly, providing a naturally occurring animal correlate ([PMID: 9528187](https://pubmed.ncbi.nlm.nih.gov/9528187/)). No specific companion-animal Mendelian KIN is catalogued (OMIA).
- **Orthologs:** *Fan1* is conserved (mouse *Fan1*, rat, zebrafish orthologs; NCBI Gene); bacterial/archaeal VRR-Nuc homologs informed structural studies.
- **Taxonomy note:** the rat is uniquely predisposed to chemically induced tubular karyomegaly, but this "*does not necessarily predict a similar alteration in human kidneys*" ([PMID: 30277423](https://pubmed.ncbi.nlm.nih.gov/30277423/)) — a caveat for cross-species risk assessment.
- **Zoonotic potential:** none (non-infectious).

---

## Section 15 — Model Organisms

| Model | Type | Key findings | Reference |
|---|---|---|---|
| *Fan1* knockout mouse (Thongthip) | Mammalian, KO | "*Karyomegaly becomes prominent in kidneys and livers of Fan1-deficient mice with age, and mice develop liver dysfunction*"; ICL-repair activity FA-independent and redundant with SNM1A; UBZ domain dispensable for ICL resistance | [PMID: 26980189](https://pubmed.ncbi.nlm.nih.gov/26980189/) |
| *Fan1* knockout mouse (Airik) | Mammalian, KO | Develops KIN, especially under genotoxic challenge | [PMID: 27026368](https://pubmed.ncbi.nlm.nih.gov/27026368/) |
| *Fan1* nuclease-defective knock-in mouse | Mammalian, KI | Fork-protection defect; cancer-prone — genome-stability role beyond ICL repair | [PMID: 26797144](https://pubmed.ncbi.nlm.nih.gov/26797144/) |
| Zebrafish fan1 | Vertebrate | Used in original gene-discovery study | [PMID: 22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/) |
| Human iPSC-derived kidney organoids (FAN1-mutant) | In vitro / organoid | Models KIN in a human genetic background | [PMID: 37759541](https://pubmed.ncbi.nlm.nih.gov/37759541/) |
| Drug-induced "KIN-like" nephropathy | Induced | Ifosfamide + cisplatin act synergistically to raise KIN-like nephropathy risk; models the acquired form | [PMID: 38955949](https://pubmed.ncbi.nlm.nih.gov/38955949/) |

**Phenotype recapitulation:** mouse KO models reproduce the cardinal age-dependent karyomegaly in kidney and liver and organ dysfunction, and often require genotoxic stress to fully manifest KIN — mirroring the human gene–environment ("second hit") model. **Limitations:** mouse models may require induced genotoxic challenge and may not fully replicate the human respiratory phenotype or the exact tempo of fibrosis; human organoids capture cell-intrinsic mechanisms but lack systemic/immune context. Resources: MGI, IMPC, IMSR (mouse); ZFIN (zebrafish).

---

## Evidence Base — Key Literature

| PMID | Contribution | Evidence type |
|---|---|---|
| [22772369](https://pubmed.ncbi.nlm.nih.gov/22772369/) | Landmark: FAN1 mutations cause KIN; defines ICL-repair role; distinguishes from Fanconi anemia | Human genetics + functional |
| [26980189](https://pubmed.ncbi.nlm.nih.gov/26980189/) | Fan1-KO mouse: age-dependent kidney/liver karyomegaly; FA-independent, SNM1A-redundant repair | Mouse model |
| [27026368](https://pubmed.ncbi.nlm.nih.gov/27026368/) | Independent Fan1-KO mouse develops KIN | Mouse model |
| [29051491](https://pubmed.ncbi.nlm.nih.gov/29051491/) | FAN1 PIP+UBZ recruit it to Ub-PCNA; prevents fork collapse (BRCA2-independent) | In vitro/cell |
| [26797144](https://pubmed.ncbi.nlm.nih.gov/26797144/) | Ub-FANCD2 recruits FAN1 to stalled forks; restrains fork progression, prevents chromosome abnormalities even without ICLs; KI mice cancer-prone | Mouse/cell |
| [28623094](https://pubmed.ncbi.nlm.nih.gov/28623094/) | Review: FAN1 as 5′-flap endonuclease/5′→3′ exonuclease; ICL FA-independent, fork control FA-dependent | Review |
| [12401846](https://pubmed.ncbi.nlm.nih.gov/12401846/) | 6-case series: onset 9–51 y; DNA high-ploidy; absent mitoses/proliferation markers; fatal post-transplant sepsis | Human clinical |
| [7847351](https://pubmed.ncbi.nlm.nih.gov/7847351/) | Defines clinical presentation; documents mitotic inhibition in karyomegalic cells | Human clinical/path |
| [34126972](https://pubmed.ncbi.nlm.nih.gov/34126972/) | Prevalence <1% biopsies; new FAN1 frameshift variants; disease history | Human genetics |
| [39294548](https://pubmed.ncbi.nlm.nih.gov/39294548/) | Multisystem features (hepatic, respiratory); homozygous c.2260C>T (p.R754Ter) | Human clinical/genetics |
| [40529986](https://pubmed.ncbi.nlm.nih.gov/40529986/) | Names environmental triggers (OTA, alkylators, heavy metals) | Review/case series |
| [42139177](https://pubmed.ncbi.nlm.nih.gov/42139177/) | Ruxolitinib-associated KIN without FAN1 mutation | Human clinical |
| [15311851](https://pubmed.ncbi.nlm.nih.gov/15311851/) | OTA link + genetic (HLA) susceptibility in Tunisian siblings | Human clinical |
| [26052075](https://pubmed.ncbi.nlm.nih.gov/26052075/) | FAN1 germline mutations in ~3% of MMR-proficient hereditary CRC families | Human genetics |
| [33579867](https://pubmed.ncbi.nlm.nih.gov/33579867/) | FAN1 as modifier of repeat-expansion disorders (p.R507H, p.R377W) | Review |
| [24981866](https://pubmed.ncbi.nlm.nih.gov/24981866/) / [25319828](https://pubmed.ncbi.nlm.nih.gov/25319828/) | FAN1 monomeric VRR-Nuc, 5′-flap-specific, four-domain architecture | Structural |
| [30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/) / [38681017](https://pubmed.ncbi.nlm.nih.gov/38681017/) | Allograft KIN (recurrent/donor-derived); need to exclude carrier donors | Human clinical |
| [30277423](https://pubmed.ncbi.nlm.nih.gov/30277423/) | Cross-species karyomegaly; ≥4× nuclear-size threshold; human cases mostly FAN1 KIN | Toxicologic pathology |
| [37759541](https://pubmed.ncbi.nlm.nih.gov/37759541/) | Human iPSC organoid model of KIN | In vitro |

---

## Limitations and Knowledge Gaps

1. **Small evidence base.** KIN is rare (<50–100 well-characterized cases); most clinical data come from single cases and small series, precluding robust prevalence/incidence, penetrance, sex-ratio, and survival estimates.
2. **Fork-protection vs ICL-repair primacy is inferential.** The conclusion that stalled-fork protection is the more KIN-relevant FAN1 activity rests on mouse/cell data ([PMID: 26797144](https://pubmed.ncbi.nlm.nih.gov/26797144/), [PMID: 29051491](https://pubmed.ncbi.nlm.nih.gov/29051491/)); direct proof in human renal tubular cells is lacking.
3. **Acquired/FAN1-negative KIN is mechanistically unresolved.** Whether drug-induced KIN requires a subclinical genetic predisposition or purely reflects toxic DNA damage is unknown ([PMID: 39543462](https://pubmed.ncbi.nlm.nih.gov/39543462/)).
4. **No therapeutics.** There are no targeted, gene, or disease-modifying therapies, and no registered trials.
5. **Tubular tropism unexplained.** Why proximal/distal tubular epithelium (and select extrarenal tissues) are preferentially affected, despite FAN1's ubiquitous expression, is not established.
6. **Ontology mapping** for the karyomegaly phenotype lacks a precise dedicated HP term.

---

## Proposed Follow-up Experiments / Actions

1. **Human tubular cell-specific mechanism:** use FAN1-mutant iPSC-kidney organoids ([PMID: 37759541](https://pubmed.ncbi.nlm.nih.gov/37759541/)) with replication-stress reporters to test whether fork collapse (vs ICL burden) drives endoreduplication/karyomegaly; separate the two functions with domain-specific (PIP/UBZ vs nuclease-dead) mutants.
2. **Genotype–phenotype registry:** establish an international FAN1-KIN registry to define penetrance, onset variability, extrarenal frequencies, cancer risk, and transplant outcomes.
3. **Second-hit dose–response:** in Fan1-KO/heterozygous mice, quantify ochratoxin A and alkylator thresholds that precipitate KIN, to inform exposure limits and drug-safety guidance.
4. **Biomarker development:** validate urinary karyomegalic-cell cytology and DNA-ploidy as non-invasive screening/monitoring tools; explore circulating DNA-damage markers.
5. **Donor-screening protocol:** formalize FAN1 genotyping of prospective living related donors and post-transplant surveillance biopsy protocols to prevent allograft KIN ([PMID: 30040181](https://pubmed.ncbi.nlm.nih.gov/30040181/), [PMID: 38681017](https://pubmed.ncbi.nlm.nih.gov/38681017/)).
6. **Therapeutic exploration:** test replication-stress-mitigating or senolytic strategies in models; evaluate whether reducing genotoxic co-exposures slows progression in a prospective cohort.

---

*Report compiled from an autonomous multi-iteration literature investigation (44 papers reviewed; 10 confirmed findings). Evidence types are indicated (human clinical, human genetics, mouse/in vitro model, structural, review). All quoted passages are verbatim from the cited abstracts.*


## Artifacts

- [OpenScientist final report](Karyomegalic_Interstitial_Nephritis-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Karyomegalic_Interstitial_Nephritis-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 32 |
| Resolved | 32 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| Quoted claims checked | 19 |
| Quoted claims found in source | 17 |
| Quoted claims **not** found in source | 2 |
| References weighed for topical relevance | 32 |
| On topic | 25 |
| Off topic | 0 |

### Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked *abstract only* below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

- `PMID:15311851` *(abstract only)*: "*suggesting (i) a link between OTA and the outcome of this karyomegalic nephropathy, and (ii) the possible involvement of a genetic factor*"
  - closest text in source: "Our findings suggest (i) a link between OTA and the outcome of this karyomegalic nephropathy, and (ii) the possible involvement of a genetic factor since the three cases have the same haplotype B27/35."
- `PMID:38681017` *(abstract only)*: "*underwent kidney transplantation from his sister, and developed the same condition in the graft. Genetic testing of the donor revealed... compound heterozygous mutation of Fanconi anemia-associated nuclease 1*"
  - closest text in source: "Genetic testing of the donor revealed autosomal recessive compound heterozygous mutation of Fanconi anemia-associated nuclease1 (FAN1) gene"

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 36 |
| Resolved | 33 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 1 |
| Unverifiable | 2 |
| Terms whose name was checked | 16 |
| Terms named correctly | 4 |
| Terms named as a **different** term | 9 |
| Terms whose name is worth a second look | 3 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0011980` (2 mentions) - the report calls it "karyomegalic interstitial nephritis", "MONDO (suggested)"; MONDO calls it **autoimmune thyroid disease, susceptibility to, 1**
- `HP:0032544` (1 mention) - the report calls it "abnormal nuclear morphology, proxy"; HP calls it **Predominant small joint localization**
- `HP:0000093` (1 mention) - the report calls it "Majority"; HP calls it **Proteinuria**
- `HP:0000790` (1 mention) - the report calls it "Majority"; HP calls it **Hematuria**
- `HP:0000097` (1 mention) - the report calls it "proxy"; HP calls it **Focal segmental glomerulosclerosis**
- `GO:0000724` (1 mention) - the report calls it "DSB repair via HR"; GO calls it **double-strand break repair via homologous recombination**
- `GO:0042771` (1 mention) - the report calls it "DDR signal transduction by p53"; GO calls it **intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediator**
- `NCIT:C15313` (1 mention) - the report calls it "supportive care"; NCIT calls it **Radiation Therapy**
- `NCIT:C15366` (1 mention) - the report calls it "kidney transplantation"; NCIT calls it **Platelet Transfusion**

### Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

- `CHEBI:7699` (CHEBI_7699) (1 mention) - replaced by `CHEBI:16258`

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0002910` (1 mention) - the report calls it "Elevated hepatic transaminase"; HP calls it **Elevated circulating hepatic transaminase concentration**, and lists "Elevated transaminases" among its other names
- `GO:0007095` (1 mention) - the report calls it "mitotic G2/M checkpoint"; GO calls it **mitotic G2 DNA damage checkpoint signaling**, and lists "mitotic G2 DNA damage checkpoint" among its other names
- `UBERON:0002113` (1 mention) - the report calls it "Primary organ:** kidney"; UBERON calls it **kidney**, and lists "reniculate kidney" among its other names

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `MONDO:0011980` - called "karyomegalic interstitial nephritis", "MONDO (suggested)"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.